SAN FRANCISCO, CA — August 5, 2026 — Leads & Copy — Jaguar Health, Inc. announced today that its subsidiary, Napo Pharmaceuticals, Inc., has met the conditions necessary to receive a $2 million holdback payment from Future Pak, LLC. This payment is part of the U.S. commercial licensing agreement initiated in January 2026 between Jaguar and a Future Pak affiliate. Jaguar had previously received an initial $16 million in non-dilutive capital upon the agreement’s closing.
The holdback amount is the remaining portion of the upfront fee, due to Jaguar upon satisfaction of specified post-closing conditions, which have now been fulfilled.
Under the terms of the agreement, Future Pak is the exclusive marketer for Mytesi (crofelemer), a prescription drug approved by the U.S. Food and Drug Administration (FDA) for symptomatic relief of noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. Future Pak also markets Canalevia-CA1, Jaguar’s crofelemer prescription drug for chemotherapy-induced diarrhea in dogs. In March 2026, Jaguar received an additional $3 million payment from Future Pak related to this agreement. The company has the potential to receive up to $17 million in additional milestone and future payments.
Jaguar’s founder, president, and CEO, Lisa Conte, stated that the agreement with Future Pak aligns with the company’s strategic focus on its global development program for a novel liquid oral crofelemer formulation. This formulation is intended as an adjunctive treatment for rare intestinal failure (IF) conditions, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). Conte added that the IF program is expected to yield clinical milestones and is currently the subject of business development discussions that could bring in non-dilutive funds from potential licensees. Jaguar plans to seek Breakthrough Therapy Designation for crofelemer for the MVID indication and aims to file a New Drug Application (NDA) with the FDA for this indication by mid-2027.
In June 2026, Napo presented additional data from ongoing investigational studies of oral liquid crofelemer in pediatric patients with IF due to MVID and SBS-IF at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France. Patients with IF often require lifelong total parenteral nutrition (TPN) due to inadequate oral nutrient absorption. MVID is a condition with a severe natural history, and while TPN is life-sustaining, it carries risks such as liver and kidney toxicities, cognitive impairment, and negative impacts on growth and survival.
Results presented at ESPGHAN 2026 indicated that the ongoing investigations of liquid oral crofelemer have demonstrated significant reductions in parenteral support (PS) and PS normalized to body weight in pediatric IF patients treated orally for over a year, with no significant clinical or laboratory abnormalities. In one MVID patient, weekly PS requirements normalized to body weight decreased by up to 48% after more than 12 months of high-dose liquid oral crofelemer therapy. Two pediatric SBS-IF patients showed reductions in weekly PS requirements normalized to body weight of up to 40% after more than 12 months of therapy.
Crofelemer is a plant-based prescription medicine derived from the sap of the Croton lechleri tree found in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program for crofelemer that adheres to fair trade practices, ensuring quality, ecological integrity, and support for indigenous communities.
Jaguar Health, Inc., through its family of companies including Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., focuses on developing and commercializing prescription medicines derived from rainforest plants for gastrointestinal distress in humans and animals. Their efforts target rare and orphan gastrointestinal disorders with intestinal failure.
Source: Jaguar Health, Inc.
